
AI Coverage
3 days ago
Advances in AI — September 2026Latest News

Shorts










Podcasts
Videos
All News

A deep learning model developed for predicting BI-RADS assessments from dynamic contrast-enhanced (DCE) breast MRI had over a 14 percent lower AUC than radiologist evaluation in external validation testing.

While better imaging may reduce the need for additional diagnostic tests, it may also eliminate the reimbursement that comes with those additional tests.

Offering telescoping and high-flow configurations, the TriNav Advance device reportedly provides interventional radiologists with improved access to small distal vessels during liver embolization procedures.

The CARE Chest X-Ray (CXR) Triage software reportedly bolsters consistent flagging of suspicious chest X-rays for lung collapse and pneumomediastinum across reviewing readers of different experience levels.

In a study involving over 700 participants who had chest CT and brain MRI, those with diabetes and lower vertebral bone mineral density (vBMD) had a nearly five percent faster total accumulation of white matter hyperintensity (WMH) in comparison to those without diabetes.

Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.

Newly cleared findings for the adjunctive AI platform a2z-Abdo-Triage include acute appendicitis, renal traumatic injury, ureteral stone and retroperitoneal hematoma.

Can MRI-Derived Tumor Habitat Subregions Bolster Recurrence Risk Stratification in Stage 2 and 3 Breast Cancer Cases?
In multivariable external testing, tumor structure habitat phenotypes from pre-treatment MRI revealed more than a doubling of recurrence risk for women with stage 2 and stage 3 breast cancer.

Could a la carte pricing be a consideration in improving revenue for radiologists in private practice?

Catch up on the top radiology content of the past week.

Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.

Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.

Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.



























